Holen Sie sich die Stockscreener-App
18.54
16.24%
-3.6619
Schlusskurs vom Vortag:
$22.20
Offen:
$21.41
24-Stunden-Volumen:
4.07M
Relative Volume:
1.50
Marktkapitalisierung:
$2.65B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-4.8026
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
-6.98%
1M Leistung:
+1.28%
6M Leistung:
+29.13%
1J Leistung:
-35.14%
1-Tages-Spanne:
$18.55
$21.68
1-Wochen-Bereich:
$18.56
$23.96
52-Wochen-Spanne:
$6.36
$28.96
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.57 | 3.17B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.67 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.31 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
416.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.10 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.79 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne to seek accelerated approval of DMD drug on Phase I/II data - Yahoo Finance
Dyne Therapeutics (DYN) Target Price Raised to $50 by Morgan Sta - GuruFocus
Dyne Therapeutics (DYN) Stock Sees Significant Drop - GuruFocus
Dyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says - marketscreener.com
Dyne Therapeutics slides after unveiling $300 million stock offering - TradingView
Dyne Therapeutics (DYN) Stock Declines by Over 13% - GuruFocus
Dyne Therapeutics (DYN) Maintains Buy Rating with Price Target a - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Given "Buy" Rating at Chardan Capital - MarketBeat
Dyne Therapeutics stock price target raised to $23 by Bernstein on positive DMD data - Investing.com UK
HC Wainwright Has Bullish Forecast for DYN FY2029 Earnings - MarketBeat
Morgan Stanley Raises Price Target on Dyne Therapeutics to $50 From $46, Keeps Overweight Rating - marketscreener.com
Dyne Delivers In Duchenne Trial; Now Aims To ACHIEVE Myotonic Dystrophy Milestones - RTTNews
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets - Yahoo Finance
Dyne Therapeutics (DYN) Is Up 7.7% After DELIVER Trial Success and Accelerated Approval Plan – Has The Bull Case Changed? - Yahoo Finance
The Technical Signals Behind (DYN) That Institutions Follow - news.stocktradersdaily.com
Dyne Therapeutics (DYN): Assessing Valuation as DELIVER Trial Topline Data Approaches - Yahoo Finance
Dyne Therapeutics launches $300 million common stock offering - Investing.com
Dyne Therapeutics amends loan agreement, secures additional $50 million tranche By Investing.com - Investing.com South Africa
Dyne Therapeutics Amends Loan Agreement for $50 Million - TipRanks
Dyne Therapeutics Launches $300 Million Public Offering; Shares Drop After Hours - marketscreener.com
Dyne Therapeutics amends loan agreement, secures additional $50 million tranche - Investing.com
Dyne Therapeutics launches $300 million common stock offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Dyne Therapeutics announces proposed public offering of common stock - marketscreener.com
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
Dyne Therapeutics stock price target raised to $50 from $46 at Morgan Stanley - Investing.com Canada
Why Dyne Therapeutics Stock Was Blasting Higher Today - Yahoo Finance
Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
DYN: DYNE-251 showed significant dystrophin gains and functional improvements in DMD, supporting accelerated approval plans - TradingView
Baird reiterates Outperform rating on Dyne Therapeutics stock, citing positive DMD data - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up Following Analyst Upgrade - MarketBeat
HC Wainwright & Co. Raises Price Target for Dyne Therapeutics (D - GuruFocus
Transcript : Dyne Therapeutics, Inc.Special Call - marketscreener.com
Dyne Therapeutics rises after positive data for its muscle wasting drug - TradingView
HC Wainwright Forecasts Strong Price Appreciation for Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular DystrophySlideshow (NASDAQ:DYN) 2025-12-08 - Seeking Alpha
Dyne Therapeutics stock price target raised to $40 from $35 at Raymond James on positive trial data - Investing.com India
Dyne Therapeutics stock rises after positive DMD trial results By Investing.com - Investing.com South Africa
Dyne Therapeutics Says Duchenne Muscular Dystrophy Trial Meets Primary Endpoint, Shares Up Pre-Bell - marketscreener.com
Dyne Therapeutics reports positive dystrophin results for DMD therapy By Investing.com - Investing.com India
Dyne Therapeutics Announces Positive Topline Results From Phase 1/2 Deliver Trial - TradingView
DYN: Z-rostudirsen delivered significant dystrophin increases and sustained functional gains in DMD - TradingView
DYN: DELIVER trial met key endpoints, showing significant dystrophin increase and functional gains in DMD - TradingView
Dyne Therapeutics (DYN) Reports Positive Results from DELIVER Tr - GuruFocus
Dyne Therapeutics Reports Positive Phase 1/2 Trial Results - TipRanks
Dyne Therapeutics : Positive Topline Results from DELIVER Trial of Z Rostudirsen in DMD - marketscreener.com
Dyne Therapeutics Reports Positive Topline Data From Phase 1/2 DELIVER Trial Of Z-Rostudirsen In DMD - Nasdaq
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - The Manila Times
Dyne Therapeutics reports positive dystrophin results for DMD therapy - Investing.com
Dyne Therapeutics Announces Positive Results from DELIVER Trial - TradingView
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):